Form 4: Amphastar Pharmaceuticals CEO Jack Y. Zhang Reports Stock Transactions

CEO Jack Y. Zhang reports disposition of Amphastar Pharmaceuticals stock to cover tax liabilities related to vesting of restricted stock units.

Summary

• Jack Y. Zhang, CEO and Chief Scientific Officer of Amphastar Pharmaceuticals, reported the disposition of 5,753 shares of common stock on March 4, 2025, at a price of $27.62 per share to cover tax liabilities related to the vesting of restricted stock units.
• Additionally, Mary Z. Luo, Director, 10% Owner, COO, Chief Scientist, and Chairman, also reported transactions.
• Following the reported transactions, Zhang directly owns 2,502,801 shares and indirectly owns 1,102,330 shares through Mary Z. Luo and 6,827,679 shares through Applied Physics and Chemistry Laboratories, Inc.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock transactions for tax purposes.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The stock disposition may have a minor impact on shareholders due to the increased supply of shares in the market.

Key Dates

Keywords

Amphastar Pharmaceuticals, Jack Y. Zhang, Mary Z. Luo, stock disposition, Form 4, restricted stock units, tax liability, beneficial ownership, insider trading